1887

Chapter 26 : Pharmacoeconomics of Pneumococcal Conjugate Vaccines

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Pharmacoeconomics of Pneumococcal Conjugate Vaccines, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815820/9781555814083_Chap26-1.gif /docserver/preview/fulltext/10.1128/9781555815820/9781555814083_Chap26-2.gif

Abstract:

This chapter reviews key concepts in pharmacoeconomics and the pharmacoeconomic literature pertaining to pneumococcal conjugate vaccine (PCV), with an emphasis on recent work and future advances. A cost minimization analysis assumes that all interventions being analyzed result in equal health outcomes and that the primary consideration is which alternative results in lower net costs. Cost-effectiveness analyses and cost-utility analyses are used predominantly in vaccine-related pharmacoeconomic evaluations. Pharmacoeconomic evaluations of pneumococcal vaccine’s value are built upon models of pneumococcal disease burden. In order to estimate the value for money represented by the introduction of PCV, epidemiologic data on pneumococcal disease incidence need to be integrated with demographic data from the population of interest to develop a proper understanding of the numbers of cases of disease, death, and disability resulting from pneumococcal infection. Most pharmacoeconomic evaluations assumed that PCV prevents invasive pneumococcal disease, pneumonia, and otitis media. One of the greatest challenges in modeling the economic value of PCV lies in developing estimates of pneumonia incidence that are (i) in accord with the vaccine efficacy data available from clinical trials and (ii) appropriate to the population being modeled. The most common direct non-health care cost included in the studies was the value of caregiver time spent tending to sick children.

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Incremental cost-effectiveness ratio.

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Estimated percentages of total costs averted by PCV by medical versus nonmedical costs in high-income countries. incl., including.

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Estimated percentages of total costs averted by PCV by disease type (including medical and nonmedical costs) in high-income countries. IPD, invasive pneumococcal disease; incl., including.

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815820.ch26
1. Arredondo, A.,, L. Y. Lockett, and, E. de Icaza. 1995. Cost of diseases in Brazil: breast cancer, enteritis, cardiac valve disease and bronchopneumonia. Rev. Saude Publica 29:349354.
2. Arredondo, A. 1997. Costs and financial consequences of the changing epidemiological profile in Mexico. Health Policy 42:3948.
3. Asensi, F.,, M. De Jose,, M. Lorente,, F. Moraga,, V. Ciuryla,, S. Arikian,, R. Casciano, and, M. Vento. 2004. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 7:3651.
4. Bennett, J. E.,, W. Sumner,, S. M. Downs, and, D. M. Jaffe. 2000. Parents' utilities for outcomes of occult bacteremia. Arch. Pediatr. Adolesc. Med. 154:4348.
5. Berndt, E. R., and, J. A. Hurvitz. 2005. Vaccine advance-purchase agreements for low-income countries: practical issues. Health Affairs 24:653665.
6. Black, S.,, H. Shinefield,, P. Ray, et al. 1999. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, otitis media, and an update on invasive disease results of the Northern California Kaiser Permanente efficacy trial, abstr. 1398. 39th Annu. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. American Society for Microbiology, Washington, DC.
7. Black, S. B.,, H. R. Shinefield,, B. Fireman,, E. Lewis,, P. Ray,, J. Hansen,, L. Elvin,, K. M. Ensor,, J. Hackell,, G. R. Siber,, F. Malinoski,, D. Madore,, R. Kohberger,, W. Watson,, R. Austrian, and, K. Edwards. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187195.
8. Black, S. B.,, H. R. Shinefield,, S. Ling,, J. Hansen,, B. Fireman,, D. Spring,, J. Noyes,, E. Lewis,, P. Ray,, J. Lee, and, J. Hackell. 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21:810815.
9. Bos, J. M.,, H. Rumke,, R. Welte, and, M. J. Postma. 2003. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin. Ther. 25:26142630.
10. Brenzel, L.,, L. J. Wolfson,, J. Fox-Rushby,, M. Miller, and, N. A. Halsey. 2006. Vaccine-preventable diseases, p. 389411. In D. T. Jamison,, J. G. Breman,, A. R. Measham,, G. Alleyne,, M. Claeson,, D. B. Evans,, P. Jha,, A. Mills, and, P. Musgrove (ed.). Disease Control Priorities in Developing Countries, 2nd ed. Oxford University Press, New York, NY.
11. Butler, J. R.,, P. McIntyre,, C. R. MacIntyre,, R. Gilmour,, A. L. Howarth, and, B. Sander. 2004. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 22:11381149.
12. Cheng, A. K.,, H. R. Rubin,, N. R. Powe,, N. K. Mellon,, H. W. Francis, and, J. K. Niparko. 2000. Cost-utility analysis of the cochlear implant in children. JAMA 284:850856.
13. Claes, C., and, J. M. Graf von der Schulenburg. 2003. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine pnc-7 in Germany. Pharmacoeconomics 21:587600.
14. Constenla, D.,, E. Gomez,, F. de la Hoz,, R. O'Loughlin,, A. Sinha,, J. E. Valencia, and, M. T. Valenzuela. 2007. The burden of pneumococcal disease and the cost effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: a review of the evidence and a preliminary economic analysis, p. 166. Albert B. Sabin Vaccine Institute, Washington, DC.
15. De Wals, P.,, G. Petit,, L. J. Erickson,, M. Guay,, T. Tam,, B. Law, and, A. Framarin. 2003. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine 21:37573764.
16. Drummond, M. F.,, B. O'Brien,, G. L. Stoddart, and, G. W. Torrance. 2000. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford University Press, Oxford, United Kingdom.
17. Eskola, J.,, T. Kilpi,, A. Palmu,, J. Jokinen,, J. Haapakoski,, E. Herva,, A. Takala,, H. Käyhty,, P. Karma,, R. Kohberger,, G. Siber, and, P. H. Makela. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403409.
18. Ess, S. M.,, U. B. Schaad,, A. Gervaix,, S. Pinosch, and, T. D. Szucs. 2003. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 21:32733281.
19. Fox-Rushby, J. A., and, K. Hanson. 2001. Calculating and presenting disability-adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 16:326331.
20. Gold, M. R.,, J. E. Siegel,, L. B. Russell, and, M. C. Weinstein. 1996. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, NY.
21. Goldblatt, D.,, J. Southern,, L. Ashton,, P. Richmond,, P. Burbidge,, J. Tasevska,, A. Crowley-Luke,, N. Andrews,, R. Morris,, R. Borrow,, K. Cartwright, and, E. Miller. 2006. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25:312319.
22. Guzmán, N.,, F. de la Hoz,, A. Higuera,, D. Pastor, and, J. Di Fabio. 2005. Costos económicos de las neumonías en niños menores de 2 años de edad, en Colombia. Rev. Panam. Salud Publica 17:178183.
23. Hussain, H.,, H. Waters,, S. B. Omer,, A. Khan,, I. Y. Baig,, R. Mistry, and, N. Halsey. 2006. The cost of treatment for child pneumonias and meningitis in the northern areas of Pakistan. Int. J. Health Plann. Manag. 21:229238.
24. Lebel, M. H.,, J. D. Kellner,, E. L. Ford-Jones,, K. Hvidsten,, E. C. Wang,, V. Ciuryla,, S. Arikian, and, R. Casciano. 2003. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin. Infect. Dis. 36:259268.
25. Levine, O. S.,, K. L. O'Brien,, M. Knoll,, R. A. Adegbola,, S. Black,, T. Cherian,, R. Dagan,, D. Goldblatt,, A. Grange, and, B. Greenwood. 2006. Pneumococcal vaccination in developing countries. Lancet 367:18801882.
26. Lieu, T. A.,, G. T. Ray,, S. B. Black,, J. C. Butler,, J. O. Klein,, R. F. Breiman,, M. A. Miller, and, H. R. Shinefield. 2000. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283:14601468.
27. Lieu, T. A.,, T. G. McGuire, and, A. R. Hinman. 2005. Overcoming economic barriers to the optimal use of vaccines. Health Affairs 24:666679.
28. Marchetti, M., and, G. L. Colombo. 2005. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine 23:45654576.
29. McIntosh, E. D.,, P. Conway,, J. Willingham, and, A. Lloyd. 2003. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine 21:25642572.
30. McIntosh, E. D.,, P. Conway,, J. Willingham,, R. Hollingsworth, and, A. Lloyd. 2005. Pneumococcal pneumonia in the UK—how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 23:17391745.
31. Melegaro, A. and, W. J. Edmunds. 2004. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22:42034214.
32. Miller, M. A., and, L. McCann. 2000. Policy analysis of the use of hepatitis b, Haemophilus influenzae type b, Streptococcus pneumoniae conjugate and rotavirus vaccines in national immunization schedules. Health Econ. 9:1935.
33. Moore, D.,, M. Bigham, and, D. Patrick. 2003. Modeling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Can. Commun. Dis. Rep. 29:97104.
34. Murray, C. J. L., and, A. D. Lopez. 1996. The Global Burden of Disease, 1st ed., vol. 1, p. 990. World Health Organization, Geneva, Switzerland.
35. Navas, E.,, L. Salleras,, R. Gisbert,, A. Dominguez,, E. Timoner,, D. Ibanez, and, A. Prat. 2005. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine 23:23422348.
36. Oh, P. I.,, P. Maerov,, D. Pritchard,, S. R. Knowles,, T. R. Einarson, and, N. H. Shear. 1996. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin. Ther. 18:160182.
37. Oostenbrink, R.,, A. M. Ha, and, M. L. Essink-Bot. 2002. The EQ-5D and the health utilities index for permanent sequelae after meningitis: a head-to-head comparison. J. Clin. Epidemiol. 55:791799.
38. Pan American Health Organization. 2006. Financial sustainability of national immunization programs. Immun. Newsl. 28:6.
39. Pepper, P. V., and, D. K. Owens. 2000. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin. Infect. Dis. 30:157164.
40. Prosser, L. A.,, G. T. Ray,, M. O'Brien,, K. Kleinman,, J. Santoli, and, T. A. Lieu. 2004. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 113:283290.
41. Ray, G. T.,, C. G. Whitney,, B. H. Fireman,, V. Ciuryla, and, S. B. Black. 2006. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J. 25:494501.
42. Salo, H.,, H. Sintonen,, J. Pekka Nuorti,, M. Linna,, H. Nohynek,, J. Verho, and, T. Kilpi. 2005. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand. J. Infect. Dis. 37:821832.
43. Shepard, D. S.,, J. A. Walsh,, E. Kleinau,, S. Stansfield, and, S. Bhalotra. 1995. Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach. Vaccine 13:707714.
44. Sinha, A.,, O. S. Levine,, M. D. Knoll,, F. Muhib, and, T. A. Lieu. 2007. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality. Lancet 369:389396.
45. Stone, P. W.,, S. Teutsch,, R. H. Chapman,, C. Bell,, S. J. Goldie, and, P. J. Neumann. 2000. Cost-utility analyses of clinical preventive services: published ratios, 1976–1997. Am. J. Prevent. Med. 19:1523.
46. Weycker, D.,, E. Richardson, and, G. Oster. 2000. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs. Am. J. Manag. Care 6(10 Suppl.):S526S535.
47. Wisloff, T.,, T. G. Abrahamsen,, M. A. Bergsaker,, O. Lovoll,, P. Moller,, M. K. Pedersen, and, I. S. Kristiansen. 2006. Cost effectiveness of adding 7-valent pneumococcal conjugate (pcv-7) vaccine to the Norwegian childhood vaccination program. Vaccine 24:56905699.
48. World Health Organization. 2001. Review of Treatment Cost Protocol Studies, WHO/V&B/01.22. Report of a Meeting, Geneva, 11–12 December 2000. World Health Organization, Geneva, Switzerland.
49. World Health Organization. 2002. World Health Report, 2002. Reducing Risks, Promoting Healthy Life. World Health Organization, Geneva, Switzerland.
50. World Health Organization. 27 February 2007, accession date. Global Immunization Data. World Health Organization, Geneva, Switzerland. http://www.who.int/immunization_monitoring/data/GlobalImmunizationData.pdf.

Tables

Generic image for table
Table 1

Types of pharmacoeconomic evaluations

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26
Generic image for table
Table 2

Costs in pharmacoeconomic evaluations of pneumococcal conjugate vaccine

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26
Generic image for table
Table 3

Summary of pharmacoeconomic evaluations of heptavalent PCV in high-income countries in Australia, North America, and Europe (part 1)

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26
Generic image for table
Table 3

Summary of pharmacoeconomic evaluations of heptavalent PCV in high-income countries in Australia, North America, and Europe (part 2)

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26
Generic image for table
Table 4

Review of pharmacoeconomic evaluations for middle- and low-income countries

Citation: Sinha A, Ray G. 2008. Pharmacoeconomics of Pneumococcal Conjugate Vaccines, p 387-403. In Siber G, Klugman K, Mäkelä P (ed), Pneumococcal Vaccines. ASM Press, Washington, DC. doi: 10.1128/9781555815820.ch26

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error